Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.55 |
| ▸ | PNMT | P11086 | 1/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.54 |
| ▸ | NOS1 | P29475 | 8/20 | 0.48 |
| ▸ | NOS2 | P35228 | 8/20 | 0.48 |
| ▸ | NOS3 | P29474 | 6/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL36008 | 0.87 | LOXL2 (0.71) | LOXL2PNMTENPP2NOS1NOS2 | |
| SCHEMBL1337579 | 0.87 | MEN1 (0.40) | LOXL2PNMTENPP2NOS1NOS2 | |
| SCHEMBL10422276 | 0.87 | LOXL2 (0.71) | LOXL2PNMTENPP2NOS1NOS2 | |
| SCHEMBL29575625 | 0.84 | LOXL2 (0.67) | LOXL2PNMTENPP2NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL6018896 | 0.84 | LOXL2 (0.67) | LOXL2PNMTENPP2NOS1NOS2 | |
| Bromide SCHEMBL28362115 | 0.84 | LOXL2 (0.67) | LOXL2PNMTENPP2NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL8195914 | 0.84 | LOXL2 (0.67) | LOXL2PNMTENPP2NOS1NOS2 | |
| SCHEMBL7883952 | 0.84 | LOXL2 (0.67) | LOXL2PNMTENPP2NOS1NOS2 | |
| Ammonia Solution, Strong SCHEMBL6899866 | 0.84 | LOXL2 (0.67) | LOXL2PNMTENPP2NOS1NOS2 | |
| Water SCHEMBL28545356 | 0.84 | LOXL2 (0.67) | LOXL2PNMTENPP2NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203353-A1 | ADHESIVE FOR ENDOSCOPE AND CURED PRODUCT THEREOF, AND ENDOSCOPE AND METHOD FOR PRODUCING THE SAME | FUJIFILM CORPORATION (JP) | 2023-06-29 | — | — | US | disclosed |
| EP-2185525-B1 | PYRAZOLE 3,5 CARBOXYLATE DERIVATIVES PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2016-12-14 | — | — | EP | disclosed |
| US-9487515-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20150265586-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | DAIICHI SANKYO, INC. | 2015-09-24 | — | — | US | disclosed |
| US-8722702-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-7893075-B2 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| WO-2010063964-A2 | COSMETIC COMPOSITION FOR MAKING-UP AND/OR CARING FOR KERATIN MATERIALS AND MAKE-UP METHOD | L'OREAL (FR) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010063957-A2 | COSMETIC COMPOSITION FOR MAKING-UP AND/OR CARING FOR KERATIN MATERIALS AND MAKE-UP METHOD | L'OREAL (FR) | 2010-06-10 | — | — | WO | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1910298-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | Brystol-Myers Squibb Company (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007002313-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002313-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | KIT, FLT3, FLT1 | LOXL2 2411/4885PNMT 828/4885ENPP2 935/4885 |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | F12, F11, F7 | LOXL2 1382/4885PNMT 2000/4885ENPP2 662/4885 |
| US-20150265586-A1 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | KIT, FLT3, FLT1 | LOXL2 2411/4885PNMT 828/4885ENPP2 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.